Support Our Future Leaders

The Media Line is known for producing truthful, unbiased journalism and we are teaching future journalists to do the same. Through our signature Press and Policy Student Program, The Media Line provides an innovative opportunity for students to globalize their educational experience by connecting to an active news bureau in the Middle East, studying journalism and public policy under the mentorship of veteran journalists while earning academic credit.

These students will reshape how the world sees and understands the Middle East and, in turn, how the Middle East impacts our world. Your contribution will provide the next generation with the skills they need to uphold the highest standards of journalism and, in turn, educate our global society with integrity and respect.

Thank you!

“The Press and Policy Student Program has elevated my global awareness, supported my journalistic efforts, and propelled me on the path of future success within the news industry.”
Press and Policy Student Program Participant
Carla Warren, University of Houston
Thank you and best wishes.
 
Felice Friedson
Founder, President
Teva’s Freefall: Any Chance for a Soft Landing? (AUDIO INTERVIEW)
Teva’s Jerusalem factory is shown in 2013. (Menahem Kahana/AFP/Getty Images)

Teva’s Freefall: Any Chance for a Soft Landing? (AUDIO INTERVIEW)

Teva Pharmaceuticals, one of Israel’s largest companies and one of the world’s largest drug manufacturers, is in something of a freefall, its share prices at a 20-year-low.

Teva was always considered a blue chip stock in Israel, a company that could be relied on for solid returns, growth and steady employment by seeking out medications whose patents were about to expire and turning them into less expensive generic drugs that sold well around the world. It also introduced several highly successful patented pharmaceuticals that accounted for a large amount of its income.

But these patents have expired or are about to, and, just as bad, Teva is facing lawsuits in the United States with regard to alleged price fixing and, to a lesser extent, peripheral involvement in the manufacture of opioids.

One analyst, Dr. Alex Coman, a technology and economics specialist at the Adelson School of Entrepreneurship at Israel’s Interdisciplinary Center Herzliya, believes a lot of the company’s woes can be blamed on excessive self-confidence, and as he says in the interview that follows, “there is no medicine for acute hubris.”

Editor’s note: Teva’s Copaxone was a medication used by people with multiple sclerosis, and not Parkinson’s disease, as was mistakenly implied in one of the questions.

Did you know we’re celebrating our 20th Anniversary as the 1st American News Agency exclusively covering the Middle East?

  • The Middle East landscape is changing rapidly.
  • The roads in the region open to new possibilities.
  • The Media Line continues to pave the way to a far greater understanding of the region’s land, people, policies and governments through our trusted, fact-based news.

We’re an independent, ad-free, non-profit news agency and rely on friends like you!

Please make your gift today.
Thank you!

We paved the way to be the Trusted Mid East News you can rely on!

We’re an independent, ad-free, non-profit news agency and rely on friends like you!

Invest in the
Trusted Mideast
News source.
We are on the
front lines.

Personalize Your News
Upgrade your experience by choosing the categories that matter most to you.
Click on the icon to add the category to your Personalize news
Browse Categories and Topics
Wake up to the Trusted Mideast News source Mideast Daily News Email
By subscribing, you agree to The Media Line terms of use and privacy policy.
Wake up to the Trusted Mideast News source Mideast Daily News Email
By subscribing, you agree to The Media Line terms of use and privacy policy.